TACRINE HYDROCHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C13H14N2.ClH
Molecular Weight	234.725
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.NC1=C2CCCCC2=NC3=C1C=CC=C3

InChI

InChIKey=ZUFVXZVXEJHHBN-UHFFFAOYSA-N

InChI=1S/C13H14N2.ClH/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13;/h1,3,5,7H,2,4,6,8H2,(H2,14,15);1H

HIDE SMILES / InChI

Description
Sources: http://www.drugbank.ca/drugs/DB00382
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/cognex.html

Tacrine is a parasympathomimetic- a reversible cholinesterase inhibitor that is indicated for the treatment of mild to moderate dementia of the Alzheimer's type. An early pathophysiological feature of Alzheimer's disease that is associated with memory loss and cognitive deficits is a deficiency of acetylcholine as a result of selective loss of cholinergic neurons in the cerebral cortex, nucleus basalis, and hippocampus. Tacrine is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine at cholinergic synapses through reversible inhibition of its hydrolysis by acetylcholinesterase. If this proposed mechanism of action is correct, tacrine's effect may lessen as the disease progresses and fewer cholinergic neurons remain functionally intact. There is no evidence that tacrine alters the course of the underlying dementing process. The mechanism of tacrine is not fully known, but it is suggested that the drug is an anticholinesterase agent which reversibly binds with and inactivates cholinesterases. This inhibits the hydrolysis of acetylcholine released from functioning cholinergic neurons, thus leading to an accumulation of acetylcholine at cholinergic synapses. The result is a prolonged effect of acetylcholine. is used for the palliative treatment of mild to moderate dementia of the Alzheimer's type. Tacrine was marketed under the trade name Cognex. Because of its liver toxicity and attendant requirement for monitoring liver function, tacrine prescriptions dropped after other acetylcholinesterase inhibitors were introduced, and its use has been largely discontinued.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Acetylcholinesterase 207 Target ID: CHEMBL220 Sources: http://www.drugbank.ca/drugs/DB00382	Inhibitor 8297	500.0 nM [IC50]
Butyrylcholinesterase 46 Target ID: CHEMBL1914 Sources: http://www.drugbank.ca/drugs/DB00382	Inhibitor 8297	23.0 nM [IC50]
Histamine N-methyltransferase 10 Target ID: CHEMBL2190 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15834447	Inhibitor 8297	0.46 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Alzheimer’s disease 272 Sources: https://www.drugs.com/pro/cognex.html	Primary		Approved 8429	Cognex Approved Use Cognex® (tacrine hydrochloride capsules) is indicated for the treatment of mild to moderate dementia of the Alzheimer's type. Launch Date 1993

C_max

Value	Dose	Co-administered	Analyte	Population
15.8 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/7836549	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		TACRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
91.8 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/7836549	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		TACRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.8 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/7836549	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		TACRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Doses

Dose	Population	Adverse events
160 mg 1 times / day multiple, oral Highest studied dose Dose: 160 mg, 1 times / day Route: oral Route: multiple Dose: 160 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9236571 https://pubmed.ncbi.nlm.nih.gov/8139083	unhealthy, 71.2 years (range: 52-88 years) n = 64 Health Status: unhealthy Condition: Alzheimer's disease Age Group: 71.2 years (range: 52-88 years) Sex: M+F Population Size: 64 Sources: https://pubmed.ncbi.nlm.nih.gov/9236571 https://pubmed.ncbi.nlm.nih.gov/8139083	Disc. AE: Nausea, Vomiting... AEs leading to discontinuation/dose reduction: Nausea (21 patient) Vomiting (21 patient) Anorexia (21 patient) Dyspepsia (21 patient) Diarrhea (21 patient) Abdominal pain (21 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/9236571 https://pubmed.ncbi.nlm.nih.gov/8139083
40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf Page: p. 5	unhealthy, adult n = 146 Health Status: unhealthy Age Group: adult Population Size: 146 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf Page: p. 5	Disc. AE: Transaminases increased, Atrial fibrillation... AEs leading to discontinuation/dose reduction: Transaminases increased (1 patient) Atrial fibrillation (1 patient) Dyspnea (1 patient) Chest pain (1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf Page: p. 5
80 mg 1 times / day multiple, oral Recommended Dose: 80 mg, 1 times / day Route: oral Route: multiple Dose: 80 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf Page: p. 5	unhealthy, adult n = 150 Health Status: unhealthy Age Group: adult Population Size: 150 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf Page: p. 5	Disc. AE: Transaminases increased, Nausea... AEs leading to discontinuation/dose reduction: Transaminases increased (1 patient) Nausea (1 patient) Vomiting (1 patient) Pallor (1 patient) Vasodilatation (1 patient) Sweating increased (1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf Page: p. 5

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
			inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	CYP1A2 1054 OCT1 327 OCT3 80 OCTN2 50 P-gp 1537

Drug as victim

Target	Modality	Activity
P-gp 1537	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7928264/	inconclusive
CYP1A2 1054	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/16128907/;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014350/	yes
OCT1 327	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7928264/	yes
OCT3 80	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7928264/	yes
OCTN2 50	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7928264/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://academic.oup.com/toxsci/article-pdf/136/2/581/16686164/kft205.pdf

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:45980	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:45980
ChemicalBook	CB7699634	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7699634
MolPort	MolPort-000-881-472	https://www.molport.com/shop/molecule-link/MolPort-000-881-472
ZINC	ZINC000019014866	http://zinc15.docking.org/substances/ZINC000019014866
eMolecules	872890	https://www.emolecules.com/cgi-bin/more?vid=872890

PubMed

Title	Date	PubMed
Ketamine-induced postanesthetic delirium attenuated by tetrahydroaminoacridine.	1974 Jul	4857761
Amino acridines action on Friend's retrovirus in relation to their molecular ionization.	1989	2790144
Antiamnesic and cholinomimetic side-effects of the cholinesterase inhibitors, physostigmine, tacrine and NIK-247 in rats.	1993 Nov 30	8119309
Systemic administration of lithium chloride and tacrine but not kainic acid augments citrulline content of rat brain.	1995 Dec 27	8788450
Adverse interaction of tacrine and haloperidol.	1996 Nov	8890692
Tacrine, a reversible acetylcholinesterase inhibitor, induces myopathy.	2000 Apr 27	10817586
Reversal of Haemorrhagic Shock in Rats by Tetrahydroaminoacridine.	2001 Jan	11150921
Flumazenil and tacrine increase the effectiveness of ondansetron on scopolamine-induced impairment of spatial learning in rats.	2003 Aug	12845416
Reduction in distractibility with AF102B and THA in the macaque.	2003 Sep	14592682
Inhibition of murine cytochrome P4501A by tacrine: in vitro studies.	2004 Aug	15258105
Cholinesterase inhibitors modify the activity of intrinsic cardiac neurons.	2004 Aug	15246845
Simultaneous analysis of esterase and transferase activities in cytosol proteins from the bovine retina by using microscale non-denaturing two-dimensional electrophoresis.	2004 Jan 14	14726204
Prediction of genotoxicity of chemical compounds by statistical learning methods.	2005 Jun	15962942
Progress update: Pharmacological treatment of Alzheimer's disease.	2007	19300586
Long-term tetrahydroaminoacridine treatment and quantitative EEG in Alzheimer's disease.	2007	17982896
Current therapeutic options for Alzheimer's disease.	2007 Dec	19415128
WITHDRAWN: Tacrine for Alzheimer's disease.	2007 Jul 18	17636619
Heterologous amyloid seeding: revisiting the role of acetylcholinesterase in Alzheimer's disease.	2007 Jul 25	17653279
Allosteric modulation of muscarinic acetylcholine receptors.	2007 Sep	19305798
The investigation of structure-activity relationships of tacrine analogues: electronic-topological method.	2008 Aug 6	19662147
A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model.	2008 Oct	18534670
Rapid determination of tacrine and other drug metabolites in microsomal incubate by newly developed targeting algorithm on UHPLC/TOFMS.	2009 Dec 15	19932643
Long-lasting decreases in cocaine-reinforced behavior following treatment with the cholinesterase inhibitor tacrine in rats selectively bred for drug self-administration.	2009 Nov	19698738
Coupling an HCN2-expressing cell to a myocyte creates a two-cell pacing unit.	2009 Nov 1	19736302
Tacrine-NO donor and tacrine-ferulic acid hybrid molecules as new anti-Alzheimer agents: hepatotoxicity and influence on the cytochrome P450 system in comparison to tacrine.	2010	20533758
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.	2011 Jul 14	21599003

Patents

Sample Use Guides

In Vivo Use Guide

Oral Initially, 10 mg 4 times daily for at least 4 weeks. If well tolerated and increased serum ALT concentrations have not occurred, increase dosage to 20 mg 4 times daily; if tolerated, increase dosage in 40-mg daily increments (divided into 4 doses daily) at 4-week intervals up to a maximum of 160 mg daily (40 mg 4 times daily).

Route of Administration: Oral

In Vitro Use Guide

Tacrine (0.01-10 uM) inhibited both human and rat HNMT activity in a concentration-dependent manner, but was less potent on both human embryonic kidney and recombinant human brain HNMT than on rat kidney HNMT (IC50 values were 0.46 and 0.70 uM vs. 0.29 uM, respectively).

Name

Type

Language

TACRINE HYDROCHLORIDE

Official Name

English

TACRINE HYDROCHLORIDE [ORANGE BOOK]

Common Name

English

TACRINE HCL

Common Name

English

NSC-72108

Code

English

TACRINE HYDROCHLORIDE [MI]

Common Name

English

Tacrine hydrochloride [WHO-DD]

Common Name

English

COGNEX

Brand Name

English

TACRINE HYDROCHLORIDE [USAN]

Common Name

English

TACRINE HYDROCHLORIDE [VANDF]

Common Name

English

9-ACRIDINAMINE, 1,2,3,4-TETRAHYDRO-, MONOHYDROCHLORIDE

Common Name

English

9-Amino-1,2,3,4-tetrahydroacridine monohydrochloride

Systematic Name

English

TACRINE HYDROCHLORIDE [MART.]

Common Name

English

CI-970

Code

English

TACRINE HYDROCHLORIDE [USP IMPURITY]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C47792